Cross-Industry Partnerships: A C-suite Strategy for Healthcare Innovation

In 2024, the original article argued that healthcare executives could use cross-industry partnerships to keep pace with technological change and changing patient needs. That premise remains sound. The more important executive question is how to turn a promising relationship into a safe, scalable operating capability without surrendering mission, accountability, data stewardship, or clinical judgment.

Healthcare organizations cannot build every capability alone. Technology companies may bring artificial intelligence, cloud infrastructure, product design, and consumer interfaces. Universities may contribute research methods, specialized talent, and independent evaluation. Manufacturers may bring engineering and quality systems. Retail, hospitality, transportation, financial-services, and logistics organizations may offer expertise in access, navigation, reliability, and large-scale operations. Community organizations contribute local trust, cultural knowledge, and a view of barriers that rarely appears in an enterprise dashboard.

Diversity of capability creates opportunity, but difference also creates risk. A hospital and a technology company may use the word “pilot” to mean very different things. A university may prioritize publication, while a commercial partner prioritizes intellectual property and speed to market. A community partner may define success as access and trust, while the health system focuses on utilization or margin. None of those interests is automatically wrong. Problems arise when leaders leave them implicit.

The executive task is therefore not simply to find innovative partners. It is to design an accountable value exchange. The partnership should begin with a patient or system problem, clarify what each party contributes and receives, assign decision rights, protect people and information, test in real conditions, and create an exit path if the work does not deliver.

Choose the problem before choosing the partner

Executives often encounter a solution first: an impressive demonstration, a board introduction, a conference meeting, or a vendor proposal. That sequence encourages organizations to reshape a problem around the offered product. Reverse it. Define the population, setting, unmet need, current pathway, consequences, constraints, and desired outcome before evaluating a partner.

A useful problem statement is specific enough to guide design but open enough to permit more than one answer. “Use AI to reduce readmissions” is solution-led and vague. “Help adults with heart failure understand and complete their post-discharge plan, with earlier escalation when symptoms worsen, while reducing avoidable burden on clinicians” describes the job. It allows leaders to compare digital tools, pharmacy support, home health, transportation, remote monitoring, community services, and workflow redesign.

Verify the need with multiple forms of evidence. Combine utilization and outcome data with direct observation, staff experience, patient and caregiver interviews, equity analysis, and financial impact. Determine whether the bottleneck is knowledge, trust, access, workflow, incentives, capacity, interoperability, or accountability. A new interface will not solve a transportation barrier. A predictive model will not help if no team owns the resulting alert.

Build the partnership thesis

A partnership thesis explains why collaboration is better than building, buying, referring, licensing, or contracting through an ordinary vendor relationship. It should identify the capability gap, the partner’s distinctive contribution, the health system’s contribution, the value created jointly, and the conditions under which the relationship should end.

Complementary strengths matter more than superficial cultural similarity. A partner should fill a verified gap and be able to work within healthcare’s evidence, privacy, accessibility, and safety requirements. The health system should also be honest about what it brings. Clinical credibility, patient relationships, facilities, data, distribution, brand, regulated workflows, and frontline labor are valuable contributions, not free inputs.

Move through five partnership decisions

These are decision gates, not ceremonial phases. A partnership can stop after any gate. Leaders should not let sunk cost, executive sponsorship, or public visibility turn an uncertain pilot into an irreversible commitment. The burden of evidence should rise as exposure, dependency, and scale increase.

Use disciplined partner selection

Traditional procurement checks solvency, functionality, price, terms, security, and references. Cross-industry innovation requires a broader view. Evaluate whether the partner understands the clinical and operational context, can support evidence generation, responds transparently to failure, and will accept shared governance. Examine its business model: what does it gain from the relationship, which data or market position does it seek, and could those incentives conflict with patients or the organization?

References should include people who operated the solution, not only executives who purchased it. Ask about implementation burden, responsiveness, defects, security events, contract disputes, and what the partner did when results disappointed. Include frontline clinicians, patients, cybersecurity, privacy, compliance, legal, finance, research, operations, and equity leaders early enough to shape the decision.

Write a shared-value charter before the contract

A contract allocates legal rights and obligations. A charter creates operating clarity. It should state the problem, population, intended benefit, scope, exclusions, contributions, funding, evidence plan, decision rights, clinical accountability, data practices, communication rules, milestones, escalation, and stop conditions in language the operating team can use.

Clarify intellectual property at the level of actual outputs. Distinguish background intellectual property brought by each party from jointly developed workflows, software, inventions, training material, datasets, and evaluation methods. Address publication and attribution. Avoid agreements so restrictive that the health system cannot learn from its own implementation or safely continue care after termination.

Create governance that can make and enforce decisions

A steering committee is not enough if every issue must travel through the same monthly meeting. Partnership governance should operate at three levels. An executive forum owns strategy, major investment, risk appetite, and continuation. An operating forum owns delivery, resources, workflow, milestones, and interdependencies. A clinical and assurance forum owns safety, privacy, security, evidence, accessibility, equity, regulatory questions, and change control. Some people may serve in more than one forum, but each forum needs a defined purpose, decision rights, cadence, and escalation route.

Maintain one shared decision log. Record the issue, evidence considered, alternatives, decision owner, date, conditions, and review point. This reduces circular debate and helps new leaders understand why the partnership works as it does. It is especially important when product updates, research findings, market changes, or incidents challenge earlier assumptions.

Set a regular review rhythm that separates delivery reporting from value review. Weekly operating meetings may address implementation obstacles. Monthly assurance reviews may examine incidents, privacy, cybersecurity, equity, model or product performance, and workforce burden. Quarterly executive reviews should decide whether evidence supports continued investment, redesign, scaling, or exit. Repeatedly moving a milestone without resolving its cause is a decision to tolerate underperformance, even if no formal vote occurs.

Governance must extend across organizational boundaries during an incident. Establish one contact tree, severity definitions, notification thresholds, joint fact-finding, patient communication authority, regulatory reporting responsibilities, and recovery ownership. Practice at least one realistic scenario before broad deployment. Examples include an incorrect clinical recommendation, a privacy disclosure, a prolonged outage, a discriminatory outcome pattern, a community complaint, or the sudden loss of a critical subcontractor.

Protect data, privacy, cybersecurity, and patient agency

Data access is often treated as the price of innovation. It should instead be limited to what the defined purpose requires. Map what information will be collected, generated, inferred, transmitted, stored, combined, reused, and deleted. Identify every party and subcontractor that can access it, where it resides, how long it is retained, and what happens after the relationship ends.

HIPAA responsibilities depend on the parties’ roles and activities, not the label placed on a relationship. The U.S. Department of Health and Human Services explains that covered entities generally must use written contracts or arrangements when business associates handle protected health information on their behalf, with terms that limit uses and require safeguards. HHS also notes that not every exchange between healthcare entities creates the same business-associate relationship. Leaders should obtain fact-specific privacy and legal review rather than assuming that a memorandum of understanding, research label, or “de-identified” claim resolves the issue. See HHS guidance on business associate contracts.

Go beyond minimum contractual language. Establish data minimization, role-based access, encryption, audit logging, incident notification, vulnerability management, recovery, subcontractor controls, secure development, deletion verification, and restrictions on secondary use. Address whether data can train algorithms, support advertising, enrich another product, or be combined with consumer information. State what patients will be told and which choices they have.

Cybersecurity is a clinical continuity issue. Test how the partnership works during an interface failure, cloud outage, compromised credential, corrupted data feed, or vendor shutdown. Maintain manual alternatives and reconciliation procedures. Require timely communication about vulnerabilities and changes. A partner may operate the technology, but the healthcare organization remains accountable for safe care when it fails.

Preserve clinical accountability and regulatory clarity

New collaborators may not understand when a feature becomes part of clinical decision-making or enters a regulated product pathway. Determine intended use, users, decisions influenced, human oversight, evidence requirements, quality controls, and reporting obligations early. The FDA’s Digital Health Center of Excellence emphasizes responsible, high-quality digital health innovation and brings together policy, cybersecurity, artificial intelligence, regulatory science, and strategic partnerships. That breadth is a useful reminder: innovation and oversight should be designed together.

Assign a qualified clinical owner for any intervention that affects screening, diagnosis, treatment, monitoring, triage, referral, or patient instruction. Define when clinicians may rely on the output, when they must override it, and how disagreement is documented and reviewed. Make limitations visible at the point of use. Monitor drift, unusual conditions, performance across populations, and workflow workarounds.

Clinical governance should also cover non-digital partnerships. A transportation partner can affect access to dialysis or follow-up. A food-service collaborator can influence nutritional care. A retail location can alter privacy and escalation. A community outreach program can create expectations and referrals. Map the entire service, including handoffs and failure recovery, rather than reviewing only the partner’s immediate task.

Address competition and conflicts before they become structural

Partnership does not remove competition law, referral rules, fraud-and-abuse considerations, tax obligations, research conflicts, or procurement duties. Market allocation, exclusivity, information sharing, joint purchasing, pricing, and ownership structures require appropriate legal review. This is especially important when collaborators are current or potential competitors.

Executives should not rely on outdated healthcare-specific antitrust safe-harbor summaries. In 2023, the Federal Trade Commission withdrew earlier healthcare enforcement policy statements and said it would evaluate conduct under general antitrust and competition principles on a case-by-case basis. The practical lesson is not to avoid collaboration. It is to design the relationship around legitimate patient and operational value, limit unnecessary exchange of competitively sensitive information, document the rationale, and obtain current counsel. See the FTC’s withdrawal notice.

Use a conflict-of-interest process for executives, clinicians, researchers, board members, and advisors. Disclose financial interests, equity, consulting, intellectual property, referral relationships, and publication incentives. Define recusal and independent review. Trust is damaged when stakeholders learn about material interests after a product has entered care.

Pilot to learn, not to perform

A good pilot reduces uncertainty. It does not merely prove that a tool can operate for a small group under ideal conditions. Write the learning questions first: Does the intervention solve the intended problem? For whom? Under which conditions? What new work does it create? Which harms or exclusions appear? Can the organization support it outside the pilot team?

Select a setting representative enough to expose real constraints, but bounded enough to protect patients and operations. Define eligibility, consent or notice where applicable, training, escalation, support, downtime, data collection, and stopping rules. Include nights, weekends, language needs, accessibility, varying digital access, and staff who did not design the project. Measure adoption and fidelity as well as outcomes.

A pilot that misses its threshold can still be useful if it produces credible learning. A pilot that reports only positive anecdotes is not. Agree that both parties can examine unfavorable results. Separate communications approval from the right to suppress valid findings. Patients and frontline staff should participate in interpretation, especially when quantitative results conflict with experience.

Scale the operating model, not only the product

Scaling multiplies dependencies. A successful pilot may have benefited from extra attention, a small number of expert users, custom data cleanup, rapid vendor support, and informal workarounds. Before expansion, convert those invisible supports into a standard operating model. Define staffing, service levels, integration, training, access, support, quality assurance, monitoring, change control, incident response, and financing.

Test portability. Sites differ in patient populations, workflows, technology, capacity, labor agreements, community resources, and local regulation. Identify which elements must remain invariant for safety and which can adapt. Use a readiness assessment rather than a calendar-driven rollout. Provide local leaders with authority to pause if prerequisites are missing.

Avoid dependency without leverage. Preserve data portability, interoperability, documentation, transition assistance, and the ability to continue essential services. Track concentration risk when several critical workflows depend on one platform, cloud provider, logistics network, or community organization. Partnership resilience includes the health of the partner itself.

Apply eight executive rules

Measure partnership value as a portfolio

One project metric cannot capture the health of a strategic relationship. Use a balanced scorecard that follows value from patient benefit through operating feasibility and partnership quality. Report performance against baseline and agreed thresholds, not only activity. Stratify results where meaningful to expose uneven benefit or harm.

Review the portfolio, not just individual pilots. Count how many projects remain stalled, duplicate another effort, lack an accountable owner, depend on unfunded clinical labor, or have no credible path to scale. Retire work that no longer serves the strategy. Concentrate resources on a smaller number of partnerships capable of producing meaningful, governable capabilities.

Questions every C-suite team should ask

What capability will exist if this partnership succeeds? If the answer is only a pilot, announcement, or dashboard, the strategic value is not yet clear.

Why is partnership the right structure? Compare collaboration with building, buying, contracting, licensing, investing, or referring.

Whose problem are we solving? Confirm that patient and frontline needs lead the work rather than product availability or executive enthusiasm.

How does each party create and capture value? Surface revenue, data, intellectual property, market access, reputation, research, and mission incentives.

Who can stop the work? Name authority for safety, privacy, security, compliance, evidence, equity, and operational concerns.

What does failure look like? Define thresholds for harm, nonperformance, workload, cost, inequity, outage, or loss of trust.

Can we operate without the partner? Understand portability, continuity, concentration, transition, and institutional capability.

Will patients and communities recognize the value? Innovation should improve something meaningful in their experience, outcome, access, or agency.